Literature DB >> 25959509

PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility.

Harini Krishnan1, Edward P Retzbach1, Maria I Ramirez2, Tong Liu3, Hong Li3, W Todd Miller4, Gary S Goldberg5.   

Abstract

Podoplanin (PDPN) is a transmembrane glycoprotein that promotes tumor cell migration, invasion, and cancer metastasis. In fact, PDPN expression is induced in many types of cancer. Thus, PDPN has emerged as a functionally relevant cancer biomarker and chemotherapeutic target. PDPN contains 2 intracellular serine residues that are conserved between species ranging from mouse to humans. Recent studies indicate that protein kinase A (PKA) can phosphorylate PDPN in order to inhibit cell migration. However, the number and identification of specific residues phosphorylated by PKA have not been defined. In addition, roles of other kinases that may phosphorylate PDPN to control cell migration have not been investigated. We report here that cyclin dependent kinase 5 (CDK5) can phosphorylate PDPN in addition to PKA. Moreover, results from this study indicate that PKA and CDK5 cooperate to phosphorylate PDPN on both intracellular serine residues to decrease cell motility. These results provide new insight into PDPN phosphorylation dynamics and the role of PDPN in cell motility. Understanding novel mechanisms of PDPN intracellular signaling could assist with designing novel targeted chemotherapeutic agents and procedures.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell migration; Cyclin dependent Kinase 5; Podoplanin; Protein Kinase A; Serine phosphorylation

Mesh:

Substances:

Year:  2015        PMID: 25959509      PMCID: PMC4556139          DOI: 10.1016/j.yexcr.2015.04.019

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  46 in total

1.  Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.

Authors:  Shinya Neri; Genichiro Ishii; Tetsuhiko Taira; Tomoyuki Hishida; Junji Yoshida; Mitsuyo Nishimura; Kanji Nagai; Atsushi Ochiai
Journal:  Ann Surg Oncol       Date:  2012-06-06       Impact factor: 5.344

2.  Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth.

Authors:  Parag Patwardhan; Yongquan Shen; Gary S Goldberg; W Todd Miller
Journal:  J Biol Chem       Date:  2006-05-17       Impact factor: 5.157

3.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Authors:  Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

4.  Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Authors:  Mika Kato Kaneko; Akiko Kunita; Shinji Abe; Yuta Tsujimoto; Masashi Fukayama; Kaoru Goto; Yoshihiko Sawa; Yasuhiko Nishioka; Yukinari Kato
Journal:  Cancer Sci       Date:  2012-08-27       Impact factor: 6.716

5.  Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells.

Authors:  K Nose; H Saito; T Kuroki
Journal:  Cell Growth Differ       Date:  1990-11

6.  Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility.

Authors:  Harini Krishnan; Jhon A Ochoa-Alvarez; Yongquan Shen; Evan Nevel; Meenakshi Lakshminarayanan; Mary C Williams; Maria I Ramirez; W Todd Miller; Gary S Goldberg
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

7.  Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions.

Authors:  Leah N Cueni; Michael Detmar
Journal:  Exp Cell Res       Date:  2009-03-04       Impact factor: 3.905

Review 8.  The role of podoplanin in tumor progression and metastasis.

Authors:  Marius Raica; Anca Maria Cimpean; Domenico Ribatti
Journal:  Anticancer Res       Date:  2008 Sep-Oct       Impact factor: 2.480

9.  Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.

Authors:  Yanlin Yu; Javed Khan; Chand Khanna; Lee Helman; Paul S Meltzer; Glenn Merlino
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

10.  Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.

Authors:  Vino T Cheriyan; Ying Wang; Magesh Muthu; Shazia Jamal; Di Chen; Huanjie Yang; Lisa A Polin; Adi L Tarca; Harvey I Pass; Q Ping Dou; Sunita Sharma; Anil Wali; Arun K Rishi
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more
  17 in total

1.  Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration.

Authors:  Edward P Retzbach; Stephanie A Sheehan; Harini Krishnan; Haiyan Zheng; Caifeng Zhao; Gary S Goldberg
Journal:  Mol Carcinog       Date:  2022-04-26       Impact factor: 5.139

Review 2.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

3.  Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Authors:  Samanta Sharma; Tian Zhang; Wojciech Michowski; Vito W Rebecca; Min Xiao; Roberta Ferretti; Jan M Suski; Roderick T Bronson; Joao A Paulo; Dennie Frederick; Anne Fassl; Genevieve M Boland; Yan Geng; Jacqueline A Lees; Rene H Medema; Meenhard Herlyn; Steven P Gygi; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

4.  Expression of podoplanin correlates with prognosis in nasopharyngeal carcinoma.

Authors:  Philipp Wolber; David Schwarz; Maximilian Niemczyk; Uta Drebber; Jens Peter Klußmann; Moritz Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-18       Impact factor: 2.503

Review 5.  Podoplanin: An emerging cancer biomarker and therapeutic target.

Authors:  Harini Krishnan; Julie Rayes; Tomoyuki Miyashita; Genichiro Ishii; Edward P Retzbach; Stephanie A Sheehan; Ai Takemoto; Yao-Wen Chang; Kazue Yoneda; Jun Asai; Lasse Jensen; Lushun Chalise; Atsushi Natsume; Gary S Goldberg
Journal:  Cancer Sci       Date:  2018-05       Impact factor: 6.716

6.  New Therapeutic Strategies for Osteoarthritis by Targeting Sialic Acid Receptors.

Authors:  Paula Carpintero-Fernandez; Marta Varela-Eirin; Alessandra Lacetera; Raquel Gago-Fuentes; Eduardo Fonseca; Sonsoles Martin-Santamaria; Maria D Mayan
Journal:  Biomolecules       Date:  2020-04-21

Review 7.  Podoplanin in Inflammation and Cancer.

Authors:  Miguel Quintanilla; Lucía Montero-Montero; Jaime Renart; Ester Martín-Villar
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923

8.  A kinase of many talents: non-neuronal functions of CDK5 in development and disease.

Authors:  Samanta Sharma; Piotr Sicinski
Journal:  Open Biol       Date:  2020-01-08       Impact factor: 6.411

9.  Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways.

Authors:  Kelly L Hamilton; Stephanie A Sheehan; Edward P Retzbach; Clinton A Timmerman; Garret B Gianneschi; Patrick J Tempera; Premalatha Balachandran; Gary S Goldberg
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-17       Impact factor: 4.553

10.  CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis.

Authors:  Joshua H Bourne; Nonantzin Beristain-Covarrubias; Malou Zuidscherwoude; Joana Campos; Ying Di; Evelyn Garlick; Martina Colicchia; Lauren V Terry; Steven G Thomas; Alexander Brill; Jagadeesh Bayry; Steve P Watson; Julie Rayes
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.